Roche loses appeal to block market entry of rival cancer drug

A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Roche stakes $2bn on UCB Alzheimer’s disease treatment

30 July 2020 Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

Americas

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

26 September 2018 The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Roche loses appeal to block market entry of rival cancer drug

More on this story

Editor's picks

Editor's picks

More features